Biogen Idec said sales of its multiple-sclerosis treatment Tecfidera more than doubled in the latest quarter, helping drive a 37% surge in overall revenue.
from WSJ.com: US Business http://online.wsj.com/articles/biogen-idec-sales-surge-37-1413978489?mod=pls_whats_news_us_business_f
via IFTTT
from WSJ.com: US Business http://online.wsj.com/articles/biogen-idec-sales-surge-37-1413978489?mod=pls_whats_news_us_business_f
via IFTTT
No comments:
Post a Comment